wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q48331376-26A20FD8-779E-44F0-A6C5-B6E0A5C461D2
Q48331376-26A20FD8-779E-44F0-A6C5-B6E0A5C461D2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48331376-26A20FD8-779E-44F0-A6C5-B6E0A5C461D2
First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
P2860
Q48331376-26A20FD8-779E-44F0-A6C5-B6E0A5C461D2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48331376-26A20FD8-779E-44F0-A6C5-B6E0A5C461D2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e0d930c31b948d1966fd03952bd92c9b5f306173
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.